Fifth Third Bancorp Raises Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Fifth Third Bancorp grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 19.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,063 shares of the biopharmaceutical company’s stock after purchasing an additional 1,929 shares during the quarter. Fifth Third Bancorp’s holdings in Regeneron Pharmaceuticals were worth $6,783,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of REGN. Salomon & Ludwin LLC purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth $31,000. Traub Capital Management LLC acquired a new position in Regeneron Pharmaceuticals during the second quarter worth about $38,000. Berbice Capital Management LLC raised its holdings in Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 60 shares during the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. lifted its stake in Regeneron Pharmaceuticals by 87.5% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 35 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 1.2%

Shares of REGN opened at $793.53 on Wednesday. The company’s 50-day moving average price is $766.18 and its 200 day moving average price is $670.05. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The firm has a market cap of $83.89 billion, a P/E ratio of 19.09, a price-to-earnings-growth ratio of 2.16 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. Regeneron Pharmaceuticals’s revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the firm posted $12.07 earnings per share. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be issued a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date is Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 8.47%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the transaction, the director owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,636 shares of company stock valued at $2,862,920 over the last quarter. 7.02% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on REGN shares. Scotiabank upped their price target on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research report on Monday, November 24th. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. HSBC upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Citigroup upped their price objective on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Finally, UBS Group raised their price objective on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $793.81.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.